Clinical Trial

First-in-Human Single and Multiple Dose of HL-400

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-21.
Trial Details
NCT Number NCT06997484
Lead Sponsor Highlightll Pharmaceutical (USA) LLC
Conditions Parkinson Disease
Enrollment 86 participants
Start Date 2025-04-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-10-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-17